Form 4 for INAB IN8BIO, INC.
Accepted 2025-05-07 00:00:00 ET · period of report 2025-04-27 · accession 0001415889-25-012288 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-07 | 2025-04-30 | INAB | McCall Patrick | CFO | M - OptEx | $0.18 | +15.0K | 67.1K | +29% | +$2,700 |
| DM | 2025-05-07 | 2025-04-27 | INAB | McCall Patrick | CFO | A - Grant | — | +35.5K | 15.0K | New | — |
| DM | 2025-05-07 | 2025-04-27 | INAB | McCall Patrick | CFO | D - Sale to Iss | — | -35.5K | 5,492 | -87% | — |
| D | 2025-05-07 | 2025-04-30 | INAB | McCall Patrick | CFO | M - OptEx | $0.00 | -15.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-30 | M | A | 15,000 | $0.18 | 67,071 | D | — | — | |
| 2 | Derivative | Series B Warrants (right to buy) | 2025-04-27 | A | A | 20,492 | — | 20,492 | D | $0.45 · — to 2028-12-13 | 20,492 Common Stock | (F4) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. (F2) Fully vested and exercisable. |
| 3 | Derivative | Series B Warrants (right to buy) | 2025-04-27 | D | D | 20,492 | — | 0 | D | $1.50 · — to 2028-12-13 | 20,492 Common Stock | (F4) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. (F3) The reported securities are included within 20,492 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock. (F2) Fully vested and exercisable. |
| 4 | Derivative | Series A Warrants (right to buy) | 2025-04-30 | M | D | 15,000 | $0.00 | 0 | D | $0.18 · — to 2025-05-02 | 15,000 Common Stock | (F2) Fully vested and exercisable. |
| 5 | Derivative | Series A Warrants (right to buy) | 2025-04-27 | A | A | 15,000 | — | 15,000 | D | $0.18 · — to 2025-05-02 | 15,000 Common Stock | (F1) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged. (F2) Fully vested and exercisable. |
| 6 | Derivative | Series A Warrants (right to buy) | 2025-04-27 | D | D | 15,000 | — | 5,492 | D | $0.45 · — to 2025-10-04 | 15,000 Common Stock | (F1) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged. (F3) The reported securities are included within 20,492 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock. (F2) Fully vested and exercisable. |